Citizens Financial Group Inc. RI Invests $1.11 Million in Alnylam Pharmaceuticals, Inc. $ALNY

Citizens Financial Group Inc. RI purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter, HoldingsChannel reports. The institutional investor purchased 3,682 shares of the biopharmaceutical company’s stock, valued at approximately $1,108,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Grandfield & Dodd LLC acquired a new stake in Alnylam Pharmaceuticals in the second quarter valued at approximately $964,000. Pallas Capital Advisors LLC bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth $663,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth $50,773,000. Plato Investment Management Ltd acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth $1,099,000. Finally, J.Safra Asset Management Corp bought a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $940,000. 92.97% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ALNY. Royal Bank Of Canada cut their price objective on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. Needham & Company LLC dropped their target price on Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Bank of America cut their price target on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a research note on Tuesday, July 14th. JPMorgan Chase & Co. reduced their price target on Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Finally, Barclays lowered their price objective on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating for the company in a research note on Monday, August 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $393.86.

Insider Activity at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the sale, the director directly owned 1,582 shares in the company, valued at $473,302.76. This represents a 70.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Stock Up 1.8%

Shares of ALNY opened at $228.61 on Wednesday. The company has a market capitalization of $30.59 billion, a PE ratio of 42.49 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 12 month low of $197.81 and a 12 month high of $495.55. The stock’s 50-day moving average price is $270.12 and its two-hundred day moving average price is $299.25. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The company had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.32 billion. During the same quarter in the prior year, the firm posted ($0.51) earnings per share. The business’s quarterly revenue was up 66.9% on a year-over-year basis. On average, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.